CASE STUDIES: ONCOLOGY
Chemotherapy-induced Nausea and Vomiting
MMG supported this phase II study for the treatment of Chemotherapy-Induced Nausea and Vomiting (CINV), requiring 450 participants to be enrolled at 80 sites in Europe, Latin America, Asia, and North America.
Results
- MMG provided support for 64 of the 80 sites involved in the study
- Enrollment at the sites MMG supported increased by over 43 percent after MMG’s recruitment program initiated and, during our involvement, MMG-supported sites recruited participants at a 193 percent greater rate than the control group
